Langerhans cell histiocytosis secondary prevention

Langerhans cell histiocytosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Langerhans cell histiocytosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Langerhans cell histiocytosis secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Langerhans cell histiocytosis secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Langerhans cell histiocytosis secondary prevention
on Langerhans cell histiocytosis secondary prevention
Langerhans cell histiocytosis secondary prevention in the news
Blogs on Langerhans cell histiocytosis secondary prevention
Directions to Hospitals Treating Langerhans cell histiocytosis
Risk calculators and risk factors for Langerhans cell histiocytosis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

• Complications may include:

• Diffuse interstitial pulmonary fibrosis
• Spontaneous pneumothorax

• Children may also develop:

• Anemia caused by spreading of the tumors to the bone marrow
• Diabetes insipidus
• Lung problems that lead to lung failure
• Problems with the pituitary gland that lead to growth failure

References

Template:WikiDoc Sources